Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ariza, Xavier ^a,b,c,d   Solà, Elsa ^a,b,c,d   Elia, Chiara ^a,b,c,d   Barreto, Rogelio ^a,b,c,d   Moreira, Rebeca ^a,b,c,d   Morales Ruiz, Manuel ^a,b,c   Graupera, Isabel ^a,b,c,d   Rodríguez, Ezequiel ^a,b,c,d   Huelin, Patricia ^a,b,c,d   Solé, Cristina ^a,b,c,d   Fernández, Javier ^a,b,c,d   Jiménez, Wladimiro ^a,b,c   Arroyo, Vicente ^a,b,c,d   Ginès, Pere ^a,b,c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Instituto Reina Sofía de Investigación Nefrológica IRSIN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CLUSTERIN; CREATININE; CYSTATIN C; GLUTATHIONE TRANSFERASE; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; TREFOIL FACTOR 3; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; ACUTE KIDNEY INJURY; AREA UNDER THE CURVE; DEMOGRAPHY; DIFFERENTIAL DIAGNOSIS; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINE;

LOTUS;

ACUTE KIDNEY INJURY; ACUTE-ON-CHRONIC LIVER FAILURE; AREA UNDER CURVE; BIOMARKERS; DEMOGRAPHY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84934979792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128145     Document Type: Article

References (39)

1. Cárdenas A, Solà E, Graupera I, Ginès P. Cirrhosis and its complications. In: ACP Medicine. American College of Physicians. June 2013.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851. doi: 10.1016/S0140-6736(08)60383-9 PMID: 18328931
3. Jalan R, Ginès P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol 2012; 57:1336-1348. doi: 10.1016/j.jhep.2012.06.026 PMID: 22750750
4. Moreau R, Jalan R, Ginès P, Pavesi M, Angeli P, Cordoba J, et al. for the CANONIC Study Group. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144:1426-1437. doi: 10.1053/j.gastro.2013.02.042 PMID: 23474284
5. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805. PMID: 17326206
6. Koyner JL, Parikh CR. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol 2013; 8:1034-1042. doi: 10.2215/CJN.05150512 PMID: 23471130
7. Murray PT, Mehta RL, Shaw A, Ronco C, Endre Z, Kellum JA, et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 2014; 85:513-521. doi: 10.1038/ki.2013.374 PMID: 24107851
8. Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int 2011; 31:656-665. doi: 10.1111/j.1478-3231.2011.02495.x PMID: 21457438
9. Borkham-Kamphorst E, van de Leur E, Zimmermann HW, Karlmark KR, Tihaa L, Haas U, et al. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochim Biophys Acta 2013; 1832:660-673. doi: 10.1016/j.bbadis.2013.01.014 PMID: 23376114
10. Xu MJ, Feng D, Wu H, Wang H, Chan Y, Kolls J, et al. The liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: A critical role for IL-6/STAT3. Hepatology 2015; 61:692-702. doi: 10.1002/hep.27447 PMID: 25234944
11. Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Solà E, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012; 57:267-273. doi: 10.1016/j.jhep.2012.03.015 PMID: 22521351
12. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57:2362-2370. doi: 10.1007/s10620-012-2180-x PMID: 22562534
13. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. for the TRIBE-AKI Consortium. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60:622-632. doi: 10.1002/hep.26980 PMID: 24375576
14. Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, et al. for the TRIBE-AKI Consortium. Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. Clin J Am Soc Nephrol 2014; 9:1857-1867. doi: 10.2215/CJN.09430913 PMID: 25183658
15. Barreto R, Elia C, Solà E, Moreira R, Ariza X, Rodríguez E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol 2014; 61:35-42. doi: 10.1016/j.jhep.2014.02.023 PMID: 24613364
16. Bai JP, Bell R, Buckman S, Burckart GJ, Eichler HG, Fang KC, et al. Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J 2011; 13:274-283. doi: 10.1208/s12248-011-9265-x PMID: 21448748
17. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2:1-138.
18. Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 2013; 59:474-481. doi: 10.1016/j.jhep.2013.04.036 PMID: 23669284
19. Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53:397-417. doi: 10.1016/j.jhep.2010.05.004 PMID: 20633946
20. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol 2012; 56:S13-S24. doi: 10.1016/S0168-8278(12)60003-8 PMID: 22300462
21. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59:482-489. doi: 10.1016/j.jhep.2013.03.039 PMID: 23665185
22. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361:1279-1290. doi: 10.1056/NEJMra0809139 PMID: 19776409
23. Papper S. Hepatorenal Syndrome. In: The Kidney in Liver Disease. Epstein M (ed) Elsevier Biomedical, New York;1983:87-106.
24. Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci 2005; 62:2932-2938. PMID: 16374581
25. O'Seaghdha CM, Hwang SJ, Larson MG, Meigs JB, Vasan RS, Fox CS. Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol 2013; 24:1880-1888. doi: 10.1681/ASN.2013010019 PMID: 23990678
26. Levitsky J, Baker TB, Jie C, Ahya S, Levin M, Friedewald J, et al. Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology 2014; 60:2017-2026. doi: 10.1002/hep.27346 PMID: 25078558
27. McMahon BA, Koyner JL, Murray PT. Urinary glutathione S-transferases in the pathogenesis and diagnostic evaluation of acute kidney injury following cardiac surgery: a critical review. Curr Opin Crit Care 2010; 16:550-555. doi: 10.1097/MCC.0b013e32833fdd9a PMID: 20930627
28. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010; 5:2154-2165. doi: 10.2215/CJN.00740110 PMID: 20798258
29. Jalan R, Fernández J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60:1310-1324. doi: 10.1016/j.jhep.2014.01.024 PMID: 24530646
30. Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, et al World Gastroenterology Organization Working Party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014; 147:4-10. doi: 10.1053/j.gastro.2014.05.005 PMID: 24853409
31. Moreau R, Arroyo V. Acute on Chronic Liver Failure: A New Clinical Entity. Clin Gastroenterol Hepatol 2014 Feb 28 [Epub ahead of print].
32. Ariza X, Angeli P, Barreto R, Jalan R, Morales Ruiz M, Elia C, et al. CANONIC Study Investigators of the EASL CLIF Consortium. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a strong predictor of short-term outcome in patients with acute decompensation of cirrhosis. Relationship with Acute-on-chronic liver failure (ACLF). J Hepatol 2014; 60 (Suppl. 1):S30-S31.
33. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22:165-175. doi: 10.1681/ASN.2010060641 PMID: 21071523
34. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab 2014; 3:384-393. doi: 10.1016/j.molmet.2014.03.004 PMID: 24944898
35. Morales-Ibañez O, Domínguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology 2013; 58:1742-1756. doi: 10.1002/hep.26521 PMID: 23729174
36. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, et al. NKT-associated hedge-hog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012; 61:1323-1329. doi: 10.1136/gutjnl-2011-301857 PMID: 22427237
37. Aamann L, Vestergaard EM, Grønbæk H. Trefoil factors in inflammatory bowel disease. World J Gastroenterol. 2014; 20:3223-3230. doi: 10.3748/wjg.v20.i12.3223 PMID: 24696606
38. Srivatsa G, Giraud AS, Ulaganathan M, Yeomans ND, Dow C, Nicoll AJ. Biliary epithelial trefoil peptide expression is increased in biliary diseases. Histopathology. 2002; 40:261-268. PMID: 11895492
39. Sasaki M, Tsuneyama K, Saito T, Kataoka H, Mollenhauer J, Poustka A, et al. Site-characteristic expression and induction of trefoil factor family 1, 2 and 3 and malignant brain tumor-1 in normal and diseased intrahepatic bile ducts relates to biliary pathophysiology. Liver Int. 2004; 24:29-37. PMID: 15101998